Diabetes Research and Clinical Practice
Volume 56, Issue 2 , Pages 101-106 , May 2002

Glucagon-like peptide-1 response to acarbose in elderly type 2 diabetic subjects

Received 3 January 2001 ,Revised 5 September 2001 ,Accepted 31 October 2001.

References 

  1. Nauck MA, Holst JJ, Willms B, Schmiegel W. Glucagon-like peptide-1 (GLP-1) as a new therapeutic approach for type 2 diabetes. Exp. Clin. Endocrinol. Diab. 1997;105:187–195
  2. Qualmann CH, Nauck MA, Holst JJ, Orskov C, Creutzfeldt W. Glucagon-like peptide-1 (GLP-1) [7–36 amide] secretion in response to luminal sucrose from the upper and lower gut. A study using α-glucosidase inhibition (acarbose). Scand. J. Gastroenterol. 1995;30:892–896
  3. Seifarth C, Bergmann J, Holst JJ, Ritzel R, Schmiegel W, Nauck MA. Prolonged and enhanced secretion of glucagons-like peptide 1 (7–36 amide) after oral sucrose due to alpha-glucosidase inhibition (acarbose) in type 2 diabetic patients. Diab. Med. 1998;15:485–491
  4. Fukase N, Takahashi H, Manaka H, et al.  Differences in glucagon-like peptide-1 and GIP responses following sucrose ingestion. Diab. Res. Clin. Pract. 1992;15:187–195
  5. Goke B, Fuder H, Wieckhorst G, Theiss U, Stridde E, Littke T, et al. Voglibose (AO-128) is an efficient α-glucosidase inhibitor and mobilizes endogenous GLP-1 reserve. Digestion. 1995;56:493–501
  6. MacIntosh CG, Andrews JM, Jones KL, Wishort JM, Mollis HA, Jensen JB, et al. Effects of age on concentrations of plasma cholecystokinin, glucagons-like peptide-1 and peptide YY and their relation to appetite and pyloric motility. Am. J. Clin. Nutr. 1999;59:999–1006
  7. Ranganath L, Sedgwick I, Morgan L, Wright J, Marks V. The aging entero-insular axis. Diabetologia. 1998;41:1309–1313
  8. Mannucci E, Ognibene A, Cremasco F, Bardini G, Mencucci A, Pierazzuoli E, et al. Glucagon-like peptide (GLP)-1 and leptin concentrations in obese patients with type 2 diabetes mellitus. Diab. Med. 2000;17:713–719
  9. Vilsboll T, Krarup T, Deacon CF, Madsbad S, Holst JJ. Reduced postprandial concentrations of intact biologically active glucagons-like peptide 1 in type 2 diabetic patients. Diabetes. 2001;50:609–613
  10. Vaag AA, Holst JJ, Volund A, Beck-Nielsen HB. Gut incretin hormones in identical twins discordant for non-insulin-dependent diabetes mellitus (NIDDM)-evidence for deceased glucagons-like peptide 1 secretion during oral glucose ingestion in NIDDM twins. Eur. J. Endocrinol. 1996;135:425–432
  11. Rabvasa-Lhoret R, Chiasson JL. Potential of α-glucosidase inhibitors in elderly patients with diabetes mellitus and impaired glucagons tolerance. Drugs Aging. 1998;13:131–143
  12. Mooradian AD. Drug therapy of non-insulin dependent diabetes in the elderly. Drugs. 1996;51:931–941
  13. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 20 (1997) 1183–1197.
  14. Mooradian AD, Albert SG, Wittry S, Chehade J, Kim J, Bellrichard B. Dose-response profile of acarbose in older subjects with type 2 diabetes. Am. J. Med. Sci. 2000;319:334–337
  15. Johnston PS, Lebovitz HE, Coniff RF, Simonson DC, Raskin P, Munera CL. Advantages of alpha-glucosidase inhibition as monotherapy in elderly type 2 diabetic patients. J. Clin. Endocrinol. Metab. 1998;83:1515–1522
  16. Hanefeld M, Temelkova-Kurktschiev T. The postprandial state and the risk of atherosclerosis. Diab. Med. 1997;14(Suppl 3):S6–S11
  17. Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W. Preserved incretin activity of glucagons-like peptide 1 (7–36 amide) but not of synthetic human gastric inhibitory polypeptide in patients with type 2 diabetes mellitus. J. Clin. Invest. 1993;91:301–307

PII: S0168-8227(01)00359-X

Diabetes Research and Clinical Practice
Volume 56, Issue 2 , Pages 101-106 , May 2002

Article Tools

* Image Usage & Resolution